Press Releases

Press Releases

June 9, 2022
SAN DIEGO , June 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans, LLC’s national provider network, providing enhanced care to their approximately 7.5 million
May 11, 2022
Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CTD Monthly Volume in March SAN DIEGO , May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended
May 1, 2022
SAN DIEGO , May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a five-week awareness campaign to highlight important and impactful work being done to help those
April 25, 2022
SAN DIEGO , April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022 , after the market close on Wednesday, May 11, 2022 . Ron Rocca , Exagen’s President and Chief Executive
April 20, 2022
SAN DIEGO , April 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group’s Q2 Conference , which takes place May 3 rd - 4 th , 2022, in New York City at the Westin New York Grand Central
March 30, 2022
SAN DIEGO , March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network agreement with Evolutions Healthcare Systems offering access to enhanced care to participating members.
March 22, 2022
SAN DIEGO , March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE ® tests will soon surpass 90 million lives as an in-network benefit for patients. Effective June 1, 2022 , AVISE test offerings become an
Displaying 1 - 10 of 16